Investor's Business Daily on MSN
Travere Therapeutics outlook brightens as turnaround looms
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.
The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...
VegFest Kelowna returns to City Park in downtown Kelowna on Sunday, Sept. 20. It brings together local businesses, food ...
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...
Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies / AbbVie Oncology, Asud ...
Despite a wave of new therapies reshaping treatment across rare and glomerular kidney diseases, Alport syndrome has largely been left behind. Among kidney diseases evaluated by Spherix Global Insights ...
In this video from GlomCon Hawaii, Dana Rizk, MD, discusses highlights from a presentation concerning the design and ...
In this video from GlomCon Hawaii, Dana Rizk, MD, discusses the results of a phase 3 clinical trial concerning the safety and ...
Cytokinetics booked its first full quarter of MYQORZO sales on Aug. 6. Armistice Capital used the same three months to raise ...
The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several ...
Guillermo Hidalgo, MD, and Kelley Appow, MD, discuss how post-AKI follow-up standards can help reduce adverse outcomes.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results